To the Editor, Vascular access in hemodialysis patients is crucial. Vascular access monitoring to ensure access patency is important for patient survival, quality of life, and blood vessel care. The ultrasound dilution method for measuring access flow is a screening tool to assess access dysfunction. Park et al. [1] performed a single-center prospective study of the variation in access flow during hemodialysis, and we have some questions and comments.
The study showed the effects of intradialytic change in blood pressure and ultrafiltration volume on the variation in access flow. As the authors mentioned, access flow measurement is useful for vascular access surveillance. However, what can we predict based on the variable flows? We doubt whether the flow variation could help to predict vascular access events. If patient data for vascular access events (thrombosis or stenosis) were available, the authors would have more informative results.
According to the study reported by Park et al [1] , the mean vintage of access was almost 5 years with a wide range of distribution. Because the duration of dialysis may influence the vascular patency and blood flow, previous studies enrolled only the incident hemodialysis patients [2, 3] . The sample size in the study by Park et al [1] was too small to adjust for the duration of dialysis.
Finally, the heterogeneity of vascular access should have been considered in the data interpretation. Because arteriovenous grafts and native fistulae have completely different physiologies, different cutoff values for vascular patency have been recommended according to the vascular access type [3] . In Reply:
We would like to thank Drs. Ahn and Kim for their interest in our article entitled "Effect of intradialytic change in blood pressure and ultrafiltration volume on the variation in access flow measured by ultrasound dilution" and for the interesting commentary. Here I would like to provide responses to the fundamental questions raised in their letter whether we can predict vascular access stenosis or thrombosis by access flow surveillance.
In our center, we started monthly access flow surveillance by ultrasound dilution from December 2009, and referred the patients for elective angiography when the access flow has decreased by 4 25% compared with a previous measurement regardless of absolute values of access flow or clinical signs. A significant stenosis was defined as a decrease in vessel diameters by 4 50% on angiographic images, together with an increase in access flow after percutaneous transluminal angioplasty (PTA) of the stenotic lesions. Consequently, 68 patients were referred for angiography during the first year (47 fistulae, 21 grafts). Access flow has decreased by 37.7% on average (from 910 7 408 to 567 7 292 mL/min), and 84% of the patients did not have any clinical sign of vascular access stenosis. The angiography showed significant stenosis in 94% of the patients (outflow stenosis 54%, inflow stenosis 39%, mixed stenosis 7%). Access flow has increased to the previous levels after PTA (from 567 7 292 to 960 7 374 mL/min). After access flow surveillance and preemptive PTA, the mean thrombosis rate of arteriovenous fistulae significantly decreased (0.51/1,000 access days in 2009 vs. 0.17/1,000 access days in 2010 vs. 0.11/1,000 access days in 2011). These data are planned for publication in a subsequent manuscript.
Drs. Ahn and Kim reported that low initial access flow after placement could be a risk factor for the vascular access patency. I agree with them. However, low initial access flow is only one of the risk factors for the vascular access patency and does not reflect vascular access stenosis. Vascular access surveillance for stenosis is a totally different kettle of fish. It needs sequential measurement of access flow, and clinical decision for angiography should be made by trend analysis, not by absolute values of access flow. The current international guidelines (NKF-KDOQI 
